Skip to main content
Equibles
WHWK logo

WHWK · Whitehawk Therapeutics, Inc. · Metrics

Track WHWK — free

Use WHWK with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research WHWK.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$3.21 -0.04 (-1.23%)
Russell 2000 member Rebalance outlook locked
Market Cap
$180.15M
Shares
57.01M
Volume · Oct 23 222.61K Avg daily vol (3M) 362.87K

WHWK metrics

79 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$3.21
Market cap
$180.15M

Price action

20 metrics
Price change (1W)
+6.9%
Price change (30D)
-19.6%
Price change (3M)
-15.1%
Price change (6M)
-22.1%
Price change (YTD)
+34.3%
Price change (1Y)
+37.1%
Trailing year
Price change (5Y)
-88.0%
52-week high
$5.10
52-week low
$1.99
Change from 52-week high
-36.3%
Change from 52-week low
+63.3%
Annualized volatility
69.6%
Annualized volatility (3M)
59.0%
Beta
1.6
RSI (14D)
39.8
Price vs SMA 50
-19.4%
Price vs SMA 200
-14.9%
Avg volume (3M)
366,790
Relative volume
0.7
Average dollar volume
$1.47M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
57.01M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
1.0
reciprocal yield 97.5%
FCF yield
-37.0%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-42.6%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
-1.3×
EV / revenue historical average (5Y)
-1.3×
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2025-03-18

Profitability

9 metrics
Gross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
$0
Operating profit (TTM)
−$86.06M
Net income (TTM)
−$79.83M
Trailing 12 months
Diluted EPS (TTM)
$-1.92
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$0.00
Gross profit per diluted share (TTM)
$0.00
Operating profit per diluted share (TTM)
$-1.20
EBITDA per diluted share (TTM)
$-2.76
Net income per diluted share (TTM)
$-1.12
Operating cash flow per diluted share (TTM)
$-0.97
Free cash flow per diluted share (TTM)
$-0.97
Capital expenditures per diluted share (TTM)
$0.00
R&D per diluted share (TTM)
$0.89
Stock compensation per diluted share (TTM)
$0.12
Book value per share
$2.89

Growth

11 metrics
Revenue growth YoY
-72.5%
Year over year
Net income growth YoY
—
Revenue (TTM)
$0
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+20.0%
Year over year · more shares
Revenue CAGR (3Y)
-22.3%
Revenue CAGR (5Y)
-12.6%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-43.6%
Return on assets
-41.2%
Debt / equity
0.0
Current ratio
17.4
EBITDA (TTM)
−$74.44M
Free cash flow (TTM)
−$69.35M
Quick ratio
—
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$189.98M
Latest balance sheet
Cash & equivalents
$85.23M
Total assets
$193.99M
Total debt
$0

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$69.35M
Capital expenditures (TTM)
$0
R&D (TTM)
$63.49M
SG&A (TTM)
$22.57M
Stock compensation (TTM)
$8.82M
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
77
13F filer change QoQ
+15
Institutional ownership
75.8%
Conviction holders (share of 13F filers)
5.2%
Crowding (high-turnover and private-fund holders)
47.9%
Private-fund adviser ownership
47.7%
Active holders' share change QoQ
+19.7%
Holder tenure
8.6
Price vs estimated holder cost
+52.0%

Ownership (registered funds)

1 metrics
Index-fund ownership
5.4%

Short interest

3 metrics
Short interest
4.8%
Latest settlement · 7.1 days to cover
Days to cover
7.1d
Short-squeeze score
64 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1422142 CUSIP 00032Q104 13F (30d) 6 filings 6 filers Visit website Investor relations